Compare BioNTech SE - ADR (BNTX) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while GraniteShares 2x Long NVDA Daily ETF trades at $36.3. The key difference: GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | NVDL | |
|---|---|---|
Market Cap | $23.31B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $119.34 | $43.02 |
52-Week Low | $83.89 | $21.76 |
Enterprise Value | $6.60B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.40, up 5.94% with a bullish technical signal from moving averages. The ETF provides leveraged exposure to NVIDIA's AI-driven growth, though recent performance has trailed NVDA's gains. Technical indicators show mixed signals with overbought RSI levels but strong trend momentum from ADX readings.
The outlook remains tied to NVIDIA's AI leadership and upcoming earnings, offering amplified returns but with significant volatility risk from daily reset leverage. Key risks include NVDA's valuation sensitivity and leverage decay during choppy markets, requiring careful risk management for investors seeking aggressive NVDA exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
